Companies: 10,795·Total market cap: $144.5T
Nipro Corporation

Nipro Corporation

NPRRFOTCHealthcare
$9.69
$-0.27(-2.71%)
Market Cap$1.6B
P/E Ratio
52W High$9.96
52W Low$8.23
Overview

Nipro Corporation (NPRRF) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · NPRRF · as of Jun 9, 2026

Key Statistics

EPS (TTM)nprrf eps ttm · nprrf earnings per shareEarnings history
PE Ratio (TTM)nprrf pe ratio ttm · nprrf price to earningsPE Ratio deep dive
Revenue (TTM)nprrf revenue ttm · nprrf annual revenueFull revenue history
Dividend Yield1.60%does nprrf pay dividends · nprrf dividend yieldDividend history
Shares Outstandingnprrf shares outstanding · nprrf floatShares outstanding history
Next EarningsTBAnprrf earnings date · nprrf next earningsEarnings history

Stock Performance

Full History
1D-2.71%
1W-2.71%
1M-2.71%
3M-2.71%
YTD+17.74%
1Y+17.74%
5Y+13.20%

About Nipro Corporation

CEOYoshihiko Sano
IPO DateSep 3, 2018
Employees36,259
CountryJP

Nipro Corporation along with its various subsidiaries, operates as a diversified global enterprise primarily focusing on three key sectors: medical devices, pharmaceuticals, and pharmaceutical packag…

what is nipro corporation · nprrf stock overview · nipro corporation company profile · who is nipro corporation ceo · nprrf OTC · nipro corporation headquarters · nipro corporation business segments

About Stock Overview & Key Data

Nipro Corporation (NPRRF) is a Healthcare company in the Medical - Instruments & Supplies industry, listed on OTC since Sep 3, 2018. As of the latest trading session, NPRRF stock price is $9.69, with a market capitalization of $1.6B. The stock has returned +17.74% over the past 12 months and +17.74% year-to-date.

Frequently Asked Questions

As of the latest trading session, Nipro Corporation (NPRRF) stock price is $9.69. The stock is traded on OTC under the ticker symbol NPRRF. The 52-week range is $8.23 – $9.96.

NPRRF stock priceNPRRF quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice